Keyword：Elcatonin Acetate,60731-46-6,Elcatonin Acetate peptide

Bone resorption is a core process in bone metabolism, driven by osteoclasts—multinucleated cells that break down bone tissue to release calcium and phosphate into the bloodstream. Imbalanced bone resorption, characterized by excessive osteoclast activity, is the primary pathological feature of osteoporosis, Paget’s disease, and malignant hypercalcemia, leading to progressive bone loss, increased fracture risk, and severe bone pain. Elcatonin Acetate (CAS 60731-46-6), a synthetic 32-amino-acid peptide derived from eel calcitonin, has emerged as a first-line therapeutic agent for bone metabolic disorders due to its potent and specific inhibitory effects on bone resorption. Unlike natural calcitonins that rely on fragile disulfide bonds, Elcatonin Acetate features a stabilized carbon-nitrogen (C-N) bond in its cyclic structure, endowing it with enhanced enzymatic stability and prolonged bioactivity. This article systematically elucidates the molecular mechanisms by which Elcatonin Acetate suppresses bone resorption, integrates clinical evidence supporting its efficacy, and clarifies its advantages in the treatment of bone-related diseases, providing a comprehensive reference for researchers, clinicians, and pharmaceutical professionals.

The Molecular Basis of Elcatonin Acetate: Structural Optimization for Targeted Receptor Binding

The inhibitory effect of Elcatonin Acetate on bone resorption originates from its specific binding to the calcitonin receptor (CTR), a G protein-coupled receptor (GPCR) highly expressed on the surface of osteoclasts and their precursor cells. The structural uniqueness of Elcatonin Acetate is the key to its high-affinity binding and functional activation. Natural calcitonins, including salmon calcitonin and human calcitonin, contain a disulfide bond at the 1-7 cysteine residues, which forms a 16-membered cyclic structure critical for receptor recognition. However, disulfide bonds are susceptible to enzymatic cleavage in vivo, resulting in short half-lives and reduced bioavailability. To address this limitation, Elcatonin Acetate is synthesized by replacing the 1,7-cysteine residues with aminosuberic acid (Asu), forming a stable C-N bond that replaces the labile disulfide bond. This structural modification not only improves the metabolic stability of the peptide but also maintains the spatial conformation required for CTR binding, ensuring its biological activity.

Elcatonin Acetate Inhibits Osteoclast-Mediated Bone Resorption Through Multi-Level Regulation

Osteoclasts, the only cells capable of bone resorption, undergo a complex life cycle including precursor cell proliferation, differentiation into mature osteoclasts, and bone resorption via acidification and protease secretion. Elcatonin Acetate exerts its inhibitory effect on bone resorption by regulating every stage of the osteoclast life cycle, through both direct and indirect mechanisms.

Mechanistically, Elcatonin Acetate inhibits the RANKL-induced activation of nuclear factor-κB (NF-κB) and activator protein-1 (AP-1), two key transcription factors that drive osteoclast differentiation. The cAMP/PKA pathway activated by Elcatonin Acetate phosphorylates IκB kinase (IKK), leading to the degradation of IκBα and subsequent inhibition of NF-κB nuclear translocation. Meanwhile, it suppresses the phosphorylation of c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK), key components of the MAPK pathway, thereby reducing the transcriptional activity of AP-1. These effects collectively block the expression of osteoclast-specific genes, inhibiting precursor cell differentiation into mature osteoclasts. Additionally, Elcatonin Acetate induces apoptosis in mature osteoclasts by upregulating the expression of pro-apoptotic proteins such as Bax and downregulating anti-apoptotic proteins such as Bcl-2, further reducing the number of functional osteoclasts.

Mature osteoclasts adhere to the bone surface and form a sealed resorption lacuna, where they secrete protons via vacuolar H+-ATPases (v-ATPases) to acidify the microenvironment (pH ~4.5). This acidic environment dissolves the hydroxyapatite crystals in bone mineral, and CTSK and MMP-9 degrade the organic matrix (primarily type I collagen). Elcatonin Acetate directly inhibits the bone resorption function of mature osteoclasts by interfering with these processes.

Bone metabolism is a coupled process between osteoclasts (bone resorption) and osteoblasts (bone formation). Elcatonin Acetate also indirectly inhibits bone resorption by promoting osteoblast activity and regulating the bone morphogenetic microenvironment. Osteoblasts secrete osteoprotegerin (OPG), a decoy receptor for RANKL that competes with RANK to bind RANKL, thereby inhibiting osteoclast differentiation. Elcatonin Acetate upregulates the expression of OPG in osteoblasts in a dose-dependent manner, while reducing the expression of RANKL. This shifts the RANKL/OPG ratio in favor of OPG, further suppressing osteoclast formation.

Additionally, Elcatonin Acetate stimulates osteoblast proliferation and differentiation, enhancing bone formation. In vitro studies found that Elcatonin Acetate (10–50 nM) increased the alkaline phosphatase (ALP) activity of osteoblasts by 30–50% and upregulated the expression of osteoblast-specific genes such as runt-related transcription factor 2 (Runx2) and osteocalcin (OCN). Increased bone formation compensates for bone loss caused by excessive resorption, improving bone mass and structural integrity. Clinical studies have confirmed that Elcatonin Acetate treatment increases bone mineral density (BMD) of the lumbar spine and hip in osteoporosis patients, which is closely related to its balanced regulation of bone resorption and formation.

Clinical Evidence Supporting the Anti-Resorption Efficacy of Elcatonin Acetate

The inhibitory effect of Elcatonin Acetate on bone resorption has been validated in numerous preclinical studies and clinical trials, supporting its clinical application in bone metabolic disorders. A randomized controlled trial involving 240 postmenopausal osteoporosis patients found that weekly intramuscular injection of Elcatonin Acetate (40 IU) for 12 months significantly reduced the levels of bone resorption biomarkers such as urinary type I collagen N-terminal peptide (uNTX) and serum C-terminal cross-linking telopeptide of type I collagen (sCTX) by 35.2% and 28.6%, respectively, compared with the placebo group. Meanwhile, the BMD of the lumbar spine and femoral neck increased by 5.8% and 2.1%, respectively, indicating potent inhibition of bone resorption and improvement of bone mass.

Advantages of Elcatonin Acetate in Inhibiting Bone Resorption: Stability, Safety, and Tolerability

The clinical application of Elcatonin Acetate is further supported by its unique advantages in inhibiting bone resorption, stemming from its structural optimization and targeted mechanism of action. First, the C-N bond substitution in Elcatonin Acetate significantly improves its enzymatic stability, with a half-life of approximately 2 hours after intramuscular injection—3–4 times longer than that of natural salmon calcitonin (30–60 minutes). This prolonged half-life allows for less frequent administration (weekly or daily), improving patient compliance and reducing the risk of missed doses.

Conclusion and Future Perspectives

Elcatonin Acetate inhibits bone resorption through a multi-dimensional, targeted mechanism centered on high-affinity binding to CTR, direct regulation of osteoclast life cycle, indirect modulation of the bone microenvironment, and synergistic enhancement of bone formation. Its structural optimization endows it with superior stability and prolonged bioactivity, while clinical trials have confirmed its potent efficacy in reducing bone resorption biomarkers, increasing bone mineral density, and relieving bone pain in osteoporosis, Paget’s disease, and malignant hypercalcemia. With high specificity, low immunogenicity, and a favorable safety profile, Elcatonin Acetate has become an indispensable therapeutic agent for bone metabolic disorders.

Future research on Elcatonin Acetate may focus on three key directions: first, developing novel dosage forms such as transdermal patches or oral preparations to further improve patient compliance; second, exploring its combination with other anti-osteoporosis drugs (e.g., bisphosphonates, teriparatide) to achieve synergistic inhibition of bone resorption and promotion of bone formation; third, conducting large-scale, long-term clinical studies to evaluate its efficacy in preventing fractures in high-risk populations, such as elderly patients with severe osteoporosis and those with glucocorticoid-induced osteoporosis. In summary, Elcatonin Acetate’s unique mechanism of action and clinical advantages make it a promising candidate for the long-term management of bone metabolic disorders, and further research will continue to expand its clinical application scope.